MGF (mechano growth factor): the IGF-1 splice variant of damaged muscle

MGF is the muscle-specific splice variant of the IGF-1 gene that is produced locally in skeletal muscle after mechanical overload or injury. in humans the transcript is called IGF-1Ec; in rodents the analogous transcript is IGF-1Eb. the synthetic research peptide sold as MGF is typically a 24-amino-acid E-domain piece of that splice variant. there are no human randomised controlled trials of synthetic MGF and no MGF drug is FDA approved.

what is MGF?

MGF is not a separate hormone. it is one of several alternative transcripts of the IGF-1 gene. the IGF-1 gene can be spliced to produce different "E-domains" tacked onto the same core IGF-1 sequence. the IGF-1Ec variant (IGF-1Eb in rodents) is induced specifically in skeletal muscle after mechanical load, which is where the "mechano" in its name comes from.

the IGF-1 gene encodes a precursor protein that is cleaved into mature IGF-1 plus an E-peptide tail. different splice variants of the IGF-1 transcript produce different E-peptide tails, and one of those tails -- the one belonging to the IGF-1Ec transcript in humans -- defines what the field has called MGF. the cloning and early characterisation of IGF-1Ec came from the Goldspink group at the Royal Free Hospital, who showed in rodent and human muscle that mechanical overload selectively upregulated this transcript over the more familiar IGF-1Ea form [1].

the synthetic research peptide marketed as MGF is not the full splice variant. it is typically a short, 24-amino-acid synthetic peptide corresponding to the unique E-domain region of IGF-1Ec, sometimes written as "MGF E-peptide". that distinction matters because most claims about MGF's biology come from work on the E-peptide in cell culture and rodent muscle, not from work on the full intact splice variant in human trials.

how does it work?

in cell-culture and animal work, the E-domain of MGF appears to act upstream of mature IGF-1 by activating quiescent satellite cells and driving myoblast proliferation, while mature IGF-1 drives later differentiation and fusion. the receptor responsible for the E-domain effect is still debated and is not the canonical IGF-1 receptor.

the foundational mechanistic paper from the Goldspink group, by Yang and Goldspink in FEBS Letters in 2002, used a synthetic MGF E-peptide on cultured myoblasts and reported that the E-domain alone increased myoblast proliferation while inhibiting terminal differentiation, the opposite of what mature IGF-1 does in the same cells. crucially, blocking the IGF-1 receptor with a neutralising antibody did not eliminate the E-domain effect, which suggested a different receptor system was involved [2]. a 2014 follow-up by Vassilakos and colleagues confirmed using synthetic peptides corresponding to the E-domain that the unique 24-residue stretch is the bioactive part of IGF-1Ec, separable from the mature IGF-1 sequence [3].

in tissue, the prevailing model is therefore: mechanical load damages muscle, IGF-1Ec is induced locally, the E-domain wakes up satellite cells and drives them into proliferation, and the mature IGF-1 portion then drives them through differentiation and fusion into existing muscle fibres. the wider review literature, including the Matheny minireview in Endocrinology in 2010, treats MGF as a putative product of IGF-I gene expression involved in tissue repair and regeneration rather than as a stand-alone hormone [4].

what does the evidence show?

expression of IGF-1Ec mRNA in human muscle after exercise and injury is well documented. controlled human trials of the synthetic MGF E-peptide as a drug, however, do not exist. all human data are about endogenous expression, and all efficacy data on the synthetic peptide come from rodent and cell-culture work.

human expression studies, including work in the In Vivo review by Philippou in 2007, established that IGF-1Ec mRNA is induced in human skeletal muscle after resistance exercise and that the magnitude of induction varies with training status, age, and damage [5]. these are observational, expression-based studies. they describe the biology of the endogenous splice variant. they do not, on their own, justify claims about what the injected synthetic E-peptide does in a human.

the most striking preclinical work on the synthetic peptide is the 2009 study by Riddoch-Contreras and colleagues in Experimental Neurology, which reported that MGF rescued motoneurons and improved muscle function in SOD1(G93A) mice, a model of motor neuron disease [6]. that paper, together with a 2005 review by Goldspink and colleagues on MGF's potential for physical training and its risk of misuse in doping, defines the realistic scope of the evidence: interesting preclinical signals for repair and regeneration, plus serious early concern about non-medical use, with no controlled human RCT pipeline behind it [7].

community marketing tends to describe MGF as "the most powerful muscle peptide" and to attribute large hypertrophy or recovery effects in humans. that is not what the published evidence supports. the honest summary is: MGF is a real and important piece of muscle repair biology in animal models and in expression studies in humans, and the synthetic peptide is an unstudied drug in humans.

regulatory status

MGF is not approved by any major drug regulator as a medicine for any indication. it sits in the research-peptide category and is on the WADA prohibited list in sport. some product listings claim "research only" status without further qualification; that label has no regulatory force in most jurisdictions.

no MGF product is approved by the FDA, the EMA, the MHRA, or the TGA. there is no IND-stage or Phase 3 human program in the public clinical-trial registries, and the peptide has not progressed through the standard drug-development pathway.

in sport, MGF and IGF-1 splice variants are covered under WADA category S2.5 (peptide hormones, growth factors, related substances and mimetics) and are prohibited at all times. this is the same category that captures growth hormone, GHRH analogues, GHSR ghrelin agonists, and IGF-1 itself.

safety profile

there is no controlled human safety data set for synthetic MGF. preclinical work has not flagged dramatic toxicity at the doses and durations studied, but the absence of human pharmacovigilance is the salient fact.

rodent and cell-culture studies of the synthetic E-peptide have not reported overt toxicity in the published literature, but those studies were short, low-dose, and not designed for safety endpoints in humans. long-term exposure to any IGF-1 pathway activator carries a theoretical concern for accelerated growth of pre-existing malignancy, since IGF-1 signalling is mitogenic in many cell types.

the gap to teach honestly is: there are no formal human pharmacovigilance or safety studies of injected synthetic MGF. immunogenicity, injection-site reactions, and any long-term IGF-1-pathway risks are not characterised. any product sold as MGF for human use is operating outside the standard drug-safety framework.

where it fits in peptide research

MGF sits inside the IGF-1 family rather than the GHRH or ghrelin families. understanding where it fits requires keeping its splice-variant biology separate from the upstream GH-axis tools that signal through the pituitary.

the closest neighbour is PEG-MGF, a pegylated version of the same E-peptide designed to extend the very short circulating half-life. PEG-MGF is mechanistically the same molecule with different pharmacokinetics. neither is FDA approved and neither has human RCT evidence.

upstream of MGF, the GHRH-axis peptides tesamorelin and CJC-1295 raise growth hormone release and indirectly raise hepatic IGF-1, which is the systemic form of the same family of molecules. ipamorelin works at the ghrelin receptor and converges on the same pituitary GH output. MGF is therefore a downstream, local-tissue piece of the same overall axis.

for the broader picture of where muscle and recovery peptides actually have FDA-approved evidence and where they do not, the muscle-building peptides guide and the FDA-approved peptides reference are the right next stops. the free peptides and your body module covers the underlying GH/IGF-1 axis.